In this episode of The Peter Attia Drive, Peter Attia delves into liver health and its intricate connections to metabolic function. He elucidates the shift from the term NAFLD to MASSL-D, which better captures the link between fatty liver disease and metabolic conditions like insulin resistance.
The discussion covers critical aspects of diagnosing and treating liver diseases like MASSL-D, highlighting the limitations of liver enzyme tests and emphasizing the role of diagnostic tools like ultrasound and MRI. Attia also touches on the potential of emerging technologies like AI in medicine and briefly mentions the gene Klotho in the context of Alzheimer's disease.
Through conversations with experts, Attia provides a comprehensive understanding of the liver's pivotal role in overall health, underscoring the importance of addressing underlying drivers of liver disease and adopting preventative measures.
Sign up for Shortform to access the whole episode summary along with additional materials like counterarguments and context.
As Julia Guadaccharo emphasizes, the liver plays a vital role in functions like metabolism and detoxification. Losing liver functionality requires a transplant, as Peter Attia notes from clinical experience, highlighting the liver's importance.
MASSL-D (metabolic dysfunction-associated steatotic liver disease) better encompasses the link between fatty liver disease and metabolic conditions like [restricted term] resistance. Peter Attia explains MASSL-D is diagnosed based on metabolic dysfunction and [restricted term] resistance. Julia Wanacharil suggests nearly all NAFLD cases also meet MASSL-D criteria.
Top causes of liver injury like steatosis and fibrosis include MASSL-D, alcoholic liver disease, and viral hepatitis. As fibrosis progresses in diseases like MASSL-D, alcoholic liver disease, and hepatitis, the risk of liver cancer like hepatocellular carcinoma increases, Peter Attia notes.
While elevated liver enzymes like ALT and AST indicate liver stress, they don't definitively diagnose MASSL-D, per Peter Attia. He suggests ultrasound as an accessible diagnostic tool, with MRI elastography and PDFF as gold standards for quantifying liver fat and fibrosis.
Treating MASSL-D involves addressing drivers like weight loss and improving [restricted term] sensitivity, as well as eliminating aggravating factors like alcohol, highlighting liver health's ties to metabolic function.
While elevated, ALT and AST indicate liver cell stress, not necessarily impaired function. AST can also rise from muscle damage, and Attia advises investigating persistent 1.5-2x elevations.
As described by Nick Stenson and Attia, MRI techniques like elastography and fat fraction can directly quantify liver fat and fibrosis. Fibroscan provides a practical, ultrasound-based option to assess liver health non-invasively.
The episode briefly notes AI's potential to transform medicine and the gene Clotho's role in Alzheimer's as topics covered elsewhere, not the main focus here.
The episode diverged from covering lactate's ties to health and performance (discussed before) to explore other specific conditions and treatments more broadly.
1-Page Summary
During a series of interviews with experts such as Julia Guadaccharo, Joel Jamison, Zach Kohane, Dina DuBall, and George Brooks, the topic of liver health is addressed with a focus on understanding liver disease, including NAFLD and its redefined term, MASSL-D.
The liver's role in the body is multifaceted, including critical functions such as metabolism, protein synthesis, and detoxification. There is no extracorporeal support for the liver, meaning if a person goes into liver failure, the only recourse is a liver transplant. The liver's functions cannot be mimicked or replaced outside the body. Julia Wanacharil emphasized the importance of liver health and Peter Attia recalled experiences with patients that highlighted the impact of liver diseases like NAFLD.
MASSL-D has been introduced to better encompass the link between fatty liver disease and metabolic conditions such as [restricted term] resistance and metabolic syndrome. Peter Attia explains that a MASSL-D diagnosis is based on metabolic dysfunction, with patients also having [restricted term] resistance. In fact, nearly all cases of NAFLD also meet the criteria for MASSL-D, indicating a strong correlation between the two. Treating MASSL-D involves addressing the underlying drivers, such as improving [restricted term] sensitivity and supporting weight loss.
Julia implies that MASSL-D is highly prevalent among those with NAFLD, with 99.6% of individuals meeting criteria for both conditions, suggesting that MASSL-D is a more accurate characterization of the disease's etiology and its association with metabolic dysfunction.
The top causes of liver injury, like steatosis and fibrosis, include MASSL-D, alcoholic liver disease, and viral hepatitis infections. In the case of hepatitis, there are different prevention and treatment options; there’s a vaccine for Hepatitis B, while for Hepatitis C, there’s no vaccine but there are treatment options. The progression of liver diseases like MASSL-D and alcoholic liver disease, as well as infections like hepatitis, can lead to fibrosis and scarring of the liver, thereby increasing the risk of developing liver cancer.
Hepatocellular carcinoma, a lethal type of liver cancer if not caught early, is influenced by liver conditions like MASSL-D, alcoholic liver disease, and viral hepatitis. Peter Attia notes that these diseases amplify the risk of liver cancer, especi ...
Liver health and liver disease
Understanding liver health is crucial, but common testing methods like ALT and AST can be misleading as direct indicators of liver function. Advances in technology provide more specific biomarkers for liver health assessment.
Both ALT and AST, enzymes associated with hepatocyte health, may indicate liver injury when levels are elevated. This can lead to false assumptions about their effectiveness in evaluating liver function in diseases such as MASSL-D.
Attia explains that ALT and AST are enzymes produced by hepatocytes and their presence in the blood is typically a sign of liver stress rather than a direct measure of its function. He emphasizes that their release upon liver stress renders them imperfect markers for assessing liver functionality.
Further complicating the interpretation of these tests, Attia points out that AST elevation can also result from muscle damage, not just liver stress, making it an ambiguous indicator.
Attia advises that consistent elevations in ALT and AST levels, specifically from one and a half to two times the normal levels, call for additional investigation, possibly including the cessation of medications like statins which could be causing the elevation.
More reliable and less invasive options exist for assessing live ...
Biomarkers and health indicators
In a discussion slightly deviating from the central theme, the potential of various emerging technologies to revolutionize the healthcare sector is acknowledged.
While not the main subject of this episode, it's worth noting that artificial intelligence (AI) and its capacity to significantly alter the landscape of medicine is a topic previously covered on Drive podcasts.
Emerging technologies and their impact on healthcare
While the topic of lactate and its relationship to health and performance has indeed been covered in previous episodes of "The Drive," it is not the main focus of this discussion. Instead, we delve into specific medical conditions and the tr ...
Specific medical conditions and treatments
Download the Shortform Chrome extension for your browser